NCT03939624 is a clinical trial of Sodium-glucose cotransporter 2 (SGLT2) inhibitors in Type2 Diabetes, sponsored by Canadian Network for Observational Drug Effect Studies, CNODES.

Who is sponsoring NCT03939624?

NCT03939624 is sponsored by Canadian Network for Observational Drug Effect Studies, CNODES.

What drugs are being tested in NCT03939624?

Interventions in NCT03939624: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, Dipeptidyl peptidase-4 (DPP-4) inhibitors.

What condition does NCT03939624 study?

NCT03939624 studies Type2 Diabetes, Myocardial Infarction, Ischemic Stroke, Cardiovascular Death, Heart Failure, All-Cause Mortality.

Is NCT03939624 still recruiting?

NCT03939624 is currently completed. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT03939624

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events

Completed Last updated 19 September 2024

What this trial tests

trial testing Sodium-glucose cotransporter 2 (SGLT2) inhibitors in Type2 Diabetes in 419,734 participants. Completed in 1 October 2019.

Timeline

1 October 2018

Primary endpoint
1 October 2019

1 October 2019

Quick facts

Lead sponsor	Canadian Network for Observational Drug Effect Studies, CNODES
Status	Completed
Study type	OBSERVATIONAL
Enrollment	419,734
Start date	1 October 2018
Primary completion	1 October 2019
Estimated completion	1 October 2019
Sites	1 location across Canada

Drugs / interventions tested

Sodium-glucose cotransporter 2 (SGLT2) inhibitors — full drug profile →
Dipeptidyl peptidase-4 (DPP-4) inhibitors — full drug profile →

Conditions studied

Type2 Diabetes — all drugs for Type2 Diabetes →
Myocardial Infarction — all drugs for Myocardial Infarction →
Ischemic Stroke — all drugs for Ischemic Stroke →
Cardiovascular Death — all drugs for Cardiovascular Death →

Sponsor

Canadian Network for Observational Drug Effect Studies, CNODES

Who can join

18 and older, any sex, with Type2 Diabetes or Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare the risk of cardiovascular events associated with the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in comparison with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors among patients with type 2 diabetes. The investigators will carry out separate population-based cohort studies using health care databases in seven Canadian provinces and the United Kingdom. The study cohort will be defined by the initiation of a SGLT2 inhibitor or a DPP-4 inhibitor after SGLT2 inhibitors entered the market. Patients will be followed up until the occurrence of a cardiovascular event. The results from the separate sites will be combined by meta-analysis to provide an overall assessment of the risk of cardiovascular events in users of SGLT2 inhibitors. The investigators hypothesize that the use of SGLT2 inhibitors will be associated with a decreased risk of cardiovascular events in comparison with the use of DPP-4 inhibitors.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study.
Filion KB, Lix LM, Yu OH, Dell'Aniello S, et al · · 2020 · cited 83× · PMID 32967856 · DOI 10.1136/bmj.m3342

Verify or expand the search:

Other trials of Sodium-glucose cotransporter 2 (SGLT2) inhibitors

Trials testing the same drug.

NCT04017221 — Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes · completed

Other recruiting trials for Type2 Diabetes

Currently open trials in the same condition.

NCT05277558 — Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D) · recruiting
NCT05015283 — Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission · NA · recruiting
NCT05006508 — Prevention With the Health and Lifestyle Tool · NA · active not recruiting
NCT04717050 — Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity · NA · active not recruiting
NCT05220917 — Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study · active not recruiting

Other Canadian Network for Observational Drug Effect Studies, CNODES trials

Trials by the same sponsor.

NCT04334824 — Hydrochlorothiazide and Risk of Skin Cancer · completed
NCT04017221 — Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes · completed
NCT03596502 — Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs Warfarin) · completed
NCT04024865 — Domperidone and Risk of Serious Cardiac Events in Postpartum Women · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03939624 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Canadian Network for Observational Drug Effect Studies, CNODES
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03939624.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing